Hormone therapy and cognitive function: is there a critical period for benefit?
The large majority of women receiving hormone therapy initiate therapy early in life for the treatment of menopausal symptoms. However, the Women's Health Initiative Memory Study, the only randomized clinical trial to date on hormone therapy and dementia, was carried out in women age 65 and older. That trial provided important insights into the detrimental effects of hormone therapy on dementia in women initiating later in life. The generalizability of those findings to the typical hormone therapy user who initiates earlier in life is unknown. To address this important issue, this review focuses on observational trials of hormone therapy and dementia risk, randomized clinical trials of hormone therapy and cognitive function, and basic science studies. These lines of research provide suggestive, but not definitive, evidence that early initiation of hormone therapy may provide cognitive benefits, particularly to verbal memory and other hippocampally mediated functions. Other forms of hormone therapy, other cognitive domains, and cyclic hormone regimens may not conform to this "critical period hypothesis." Further research is needed to test the validity and limits of this hypothesis.
Department of Psychiatry, Center for Cognitive Medicine, Neuropsychiatric Institute MC913, University of Illinois at Chicago, 60612, USA. pmaki@psych.uic.edu
P M
PM
Maki
D002986:Clinical Trials as Topic; D003071:Cognition / Q000502:physiology*; D003072:Cognition Disorders / Q000188:drug therapy*; D003704:Dementia / Q000517:prevention & control; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008568:Memory / Q000187:drug effects / Q000502:physiology*; D008593:Menopause / Q000187:drug effects / Q000523:psychology